MHRAsafety guidance84% confidence
Guidance: AI Airlock Sandbox Phase 2 Programme Report
Source: MHRA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to pharmaceutical companies; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
The MHRA’s AI Airlock second phase ran between April 2025 and May 2026. This report does not constitute formal MHRA guidance.
Supporting Context
- Therapeutic area
- General · AI in Drug Development
- Sub-indication
- General
Related signal: MHRA Launches AI Sandbox to Enhance Medicines Development and Safety